Aller au contenu principal
Profil bibliographique

Jan Versijpt

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

6Publications signalées
1Citations signalées
2Affiliations récentes

Les institutions déclarées

Les domaines associés

Migraine and Headache StudiesTraumatic Brain Injury ResearchCardiovascular Syncope and Autonomic DisordersDementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Les publications récentes

Accès ouvert 2026 article OpenAlex

Biomarker‐Based Diagnosis and Care Pathways for Alzheimer's Disease in the Era of Disease‐Modifying Treatments: A Consensus Statement by Belgian Experts

Tim Van Langenhove, Sara Van Mossevelde, Marijke Miatton, Jan De Lepeleire et autres

BACKGROUND: The recent approval of disease-modifying therapies (DMTs) for early Alzheimer's disease (AD) marks a major shift in clinical practice. Biomarker confirmation of amyloid pathology is now required alongside clinical assessment, and blood-based tests are improving accessibility. This creates increased demand for …

be, us, bg (code pays fourni par la source)

0 citations European Journal of Neurology
Accès ouvert 2026 article OpenAlex

Tolerability, safety, and efficacy of atogepant versus topiramate in adults with migraine (TEMPLE): a randomised, head-to-head, phase 3b trial

Uwe Reuter, Annelies Van Dycke, Jan Versijpt, Dagny Holle et autres

BACKGROUND: Oral calcitonin gene-related peptide (CGRP) receptor antagonists such as atogepant have been approved for preventive treatment of migraine but have not been compared directly with conventional oral non-specific preventive treatments. Topiramate is a widely used conventional oral non-migraine-specific preventive treatment for …

de, be, hu, us (code pays fourni par la source)

0 citations The Lancet Neurology
2026 article OpenAlex

Patient-reported Outcomes Through 12-weeks of Double-blind Rimegepant Treatment for the Prevention of Episodic Migraine in Adults with Prior Inadequate Response to Oral Preventatives (P1-15.008)

Amaal Starling, Jan Versijpt, Marja‐Liisa Sumelahti, Ayşe Neslihan Aslan et autres

Evaluate change in patient-reported outcomes (PROs) with rimegepant treatment for the prevention of episodic migraine (EM) in adults with inadequate response to prior non-migraine specific oral preventive medications (OPMs).

us, be, fi, gb (code pays fourni par la source)

0 citations Neurology
Accès ouvert 2026 article OpenAlex

What’s a migraine day? Towards a consensus definition for clinical care and research – a Delphi panel-based study

Luna De Loose, Koen Paemeleire, Christina Deligianni, Christian Lampl et autres

BACKGROUND: Although guidelines for controlled trials have proposed a definition for a migraine day, substantial variability remains across clinical trials, highlighting the need for a universally adopted definition. METHODS: Through three survey rounds using an eDelphi method, a panel of 18 headache …

be, gr, at, tr, no, it, dk, es, pt, lt, rs, nl, gb, de, sa (code pays fourni par la source)

1 citation The Journal of Headache and Pain

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.